Autologous– tag –
-
BIANCA CLINIC Pioneers Regenerative Medicine in Japan with Autologous Adipose Stem Cells and Exosome Therapy under Strict Regulatory Compliance
BIANCA CLINIC Japan Overview BIANCA CLINIC in Tokyo is advancing regenerative medicine by offering exosome therapy, purified stem cell culture supernatant, and autologous adipose-derived stem cell therapy, all strictly compliant with Jap... -
BIANCA CLINIC Offers Autologous Adipose-Derived Stem Cell IV Therapy for Back Pain in Japan, Following Regenerative Medicine Regulatory Reforms
BIANCA CLINIC Japan Overview BIANCA CLINIC in Japan is offering intravenous (IV) therapy using autologous adipose-derived stem cells for back pain, aligning with Japan's legal framework reforms for regenerative medicine in 2025. This doc... -
Democratizing Immunotherapy: Tec de Monterrey Pioneers Cost-Effective NK Cell Production Using Autologous Plasma
Facebook (Tec de Monterrey) Mexico Overview A research team at Tec de Monterrey's Toluca campus in Mexico has developed an innovative method to optimize natural killer (NK) cell cultures, utilizing readily available autologous human plas... -
Next-Gen CAR-T Manufacturing Reduces Production Time to 1-2 Days, Explores Decentralized Models for Potent Cells
Bioprocess International USA Overview An article in Bioprocess International highlights advancements in next-generation CAR-T cell therapy manufacturing, which are set to reduce production times to as little as one or two days, yielding ... -
Northway Biotech Unveils €61M Lithuanian Facility to Industrialize CAR-T, Integrating Vector Supply for Next-Gen Therapies
Invest Lithuania Lithuania Overview Northway Biotech has inaugurated a €61 million, 3,500 sq. meter CDMO facility in Vilnius, Lithuania, designed to industrialize the manufacturing of allogeneic CAR-T and other advanced cell and gene the... -
CAR-T Cell Therapy Manufacturing Breakthrough: Automated Bioreactors Cut Production Time Below 48 Hours, Reduce Costs by 35%
PMC USA Overview Recent research highlights significant advances in CAR-T cell therapy manufacturing, with automated bioreactors enabling point-of-care biomanufacturing that reduces cell product time to less than 48 hours and cuts costs ... -
Automated iPSC Manufacturing Achieves Monoclonal Lines in Seven Weeks, Paving Way for Cost-Efficient Clinical Autologous Therapies
bioRxiv Unknown Overview A new study introduces a highly efficient, standardizable, and automatable workflow for generating monoclonal induced pluripotent stem cell (iPSC) lines from human skin biopsies, including comprehensive quality c... -
Allogeneic Cell Therapy Manufacturing: Challenges, Advantages, and the Key Role of Automated Bioreactors for Scalability
sdg.azte.co Global Overview This article delves into the complexities of allogeneic cell therapy manufacturing, highlighting its advantages such as scalability, off-the-shelf availability, and cost-effectiveness. The manufacturing proces... -
Japan’s Stem Cell Therapy Landscape: High Costs and Strict MHLW Regulations Govern Regenerative Medicine Hubs
PlacidWay Japan Overview Leading stem cell therapy clinics in Japan, such as Cell Grand Clinic and Clinique Haru Osaka Umeda, offer regenerative medicine for conditions like joint disorders, musculoskeletal diseases, diabetes, and Parkin... -
TScan Therapeutics Pivots to In Vivo TCR-T Therapy, Halting Allogeneic Cell Program TSC-101 Amidst Manufacturing Challenges
FirstWord Pharma USA Overview TScan Therapeutics announced a strategic pivot, discontinuing its lead allogeneic cell therapy program, TSC-101, and shifting focus to preclinical in vivo TCR-T candidates for solid tumors, citing funding co...
